Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells

Y. Q. Liu, E. Kyle, S. Patel, F. Housseau, F. Hakim, R. Lieberman, M. Pins, M. V. Blagosklonny, R. C. Bergan

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Preclinical models for the identification of prostate cancer chemoprevention agents are lacking. Based upon the notion that clinically useful chemoprevention agents should exhibit selective activity against early stage disease, studies were undertaken to assess whether chemoprevention agents selectively inhibited the growth of early stage prostate cancer, as compared to late stage cancer. First, a series of cell and molecular studies were performed, which, when taken together, validated the use of a panel of prostate cell lines as a model of the different stages of carcinogenesis. Next, therapeutic responsiveness to ten different cytotoxic or chemoprevention agents was evaluated. Chemoprevention agents exhibited selective activity against normal and early transformed prostate tissue, whereas cytotoxic agents were non-specific. Selective activity against early versus advanced prostate cancer cells is identified as a potential screening method for chemoprevention agents.

Original languageEnglish (US)
Pages (from-to)81-91
Number of pages11
JournalProstate Cancer and Prostatic Diseases
Volume4
Issue number2
DOIs
StatePublished - Jul 24 2001

Keywords

  • Cell growth
  • Chemoprevention
  • Preclinical models
  • Prostate cancer
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Fingerprint Dive into the research topics of 'Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells'. Together they form a unique fingerprint.

  • Cite this